However, we found that the elevated fractional clearance of Lp(a) with alirocumab could not reduce Lp(a) concentrations into a normal range, implying that, despite PCSK9 inhibition, patients remain at increased residual risk of ASCVD. Here, LPA is linked to atherosclerosis.